Michael Floyd - Nov 1, 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Operating Officer
Signature: /s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol: PCSA
Transactions as of: Nov 1, 2021
Transactions value $: $0
Form type: 4
Date filed: 4/4/2022, 05:50 PM
Previous filing: Oct 8, 2021
Next filing: Jan 6, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Gift	$0	-7K	-8.98%	$0.00	70.9K	Mar 31, 2022	Direct	F1
holding	PCSA	Common Stock						66.3K	Nov 1, 2021	by Elion Oncology, Inc.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock Units	Award	$0	+4.29K	+18.81%	$0.00	27.1K	Nov 1, 2021	Common Stock	4.29K	$0.00	Direct	F2
transaction	PCSA	Restricted Stock Units	Award	$0	+10.7K	+39.59%	$0.00	37.8K	Mar 31, 2022	Common Stock	10.7K	$0.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting.
F2	Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.